Frontiers in Immunology (Nov 2018)

Unraveling SSc Pathophysiology; The Myofibroblast

  • Arjan van Caam,
  • Madelon Vonk,
  • Frank van den Hoogen,
  • Peter van Lent,
  • Peter van der Kraan

DOI
https://doi.org/10.3389/fimmu.2018.02452
Journal volume & issue
Vol. 9

Abstract

Read online

Systemic sclerosis (SSc) is a severe auto-immune disease, characterized by vasculopathy and fibrosis of connective tissues. SSc has a high morbidity and mortality and unfortunately no disease modifying therapy is currently available. A key cell in the pathophysiology of SSc is the myofibroblast. Myofibroblasts are fibroblasts with contractile properties that produce a large amount of pro-fibrotic extracellular matrix molecules such as collagen type I. In this narrative review we will discuss the presence, formation, and role of myofibroblasts in SSc, and how these processes are stimulated and mediated by cells of the (innate) immune system such as mast cells and T helper 2 lymphocytes. Furthermore, current novel therapeutic approaches to target myofibroblasts will be highlighted for future perspective.

Keywords